Generation of Induced Pluripotent Stem Cells with CytoTune, a Non-Integrating Sendai Virus

Primary and Stem Cell Systems, Life Technologies, Carlsbad, CA, USA.
Methods in molecular biology (Clifton, N.J.) (Impact Factor: 1.29). 04/2013; 997:45-56. DOI: 10.1007/978-1-62703-348-0_5
Source: PubMed


One of the major obstacles in generating induced pluripotent stem cells for research or downstream applications is the potential modifications of cellular genome as a result of using integrating viruses during reprogramming. Another major disadvantage of reprogramming cells with integrating vectors is that silencing and activation of transgenes are unpredictable, which may affect terminal differentiation potential and increase the risk of using iPSC-derived cells. Here we describe a protocol for the generation of induced pluripotent stem cells using a non-integrating RNA virus, Sendai virus, to efficiently generate transgene-free iPSCs starting with different cell types as well as in feeder-free conditions.

Download full-text


Available from: Mohan Vemuri, Jul 14, 2015
    • "iPSCs have the capacity to differentiate into patient specific cell types, therefore reducing the likelihood of immunological rejection. Since the first report by Nobel Prize laureate Yamanaka that iPSCs could be generated from fibroblasts through the introduction of specific transcription factors using retroviral systems (Takahashi et al., 2007; Takahashi and Yamanaka, 2006), more effective, non-integrative techniques involving the use of Sendai virus have been described (Lieu et al., 2013). Thus, it is currently possible to generate iPSCs from a person's somatic cells and differentiate them into the required functional cell type (Wilson and Wu, 2015): notably, a first human clinical trial is using iPSC-derived retinal pigment epithelium cells to evaluate their efficacy in treating macular degeneration (Reardon and Cyranoski, 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Induced pluripotent stem cells (iPSCs) are a promising tool for regenerative medicine in chronic conditions associated with muscle atrophy since iPSCs are easier to obtain, pose less ethical limitations and can better capture human genetic diversity compared with human embryonic stem cells. We highlight the potentiality of iPSCs for treating muscle-affecting conditions for which no effective cure is yet available, notably aging sarcopenia and inherited neurometabolic conditions. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Journal of Cellular Physiology 07/2015; DOI:10.1002/jcp.25114 · 3.84 Impact Factor
  • Source
    • "Induced PSC were generated from freshly collected, peripheral blood-derived PBMC (Chou et al., 2011). Cells were transduced with the integration-free CytoTune-iPS Sendai Reprogramming Kit, which utilizes Sendai virus particles of the four Yamanaka factors (Lieu et al., 2013; Takahashi et al., 2007). Transduced cells were plated with MEF feeder cells, and fed iPSC medium with freshly added bFGF (Invitrogen) until small colonies were formed in about 2 weeks. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral blood mononuclear cells (PBMC) were donated by a patient with clinically diagnosed frontotemporal dementia (FTD). Induced pluripotent stem cells (iPSCs) were developed using integration-free CytoTune-iPS Sendai Reprogramming factors which include Sendai virus particles of the four Yamanaka factors Oct, Sox2, Klf4, and c-Myc. Published by Elsevier B.V.
    Stem Cell Research 07/2015; 15(2):325-327. DOI:10.1016/j.scr.2015.07.004 · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are currently no known treatment options that actually halt or permanently reverse the pathology evident in any neurodegenerative condition. Arguably, one of the most promising avenues for creating viable neuronal treatments could involve the combined use of cell replacement and gene therapy. Given the complexity of the neurodegenerative process, it stands to reason that adequate therapy should involve not only the replacement of loss neurons/synapses but also the interruption of multiple pro-death pathways. Thus, we propose the use of stem cells that are tailored to express specific trophic factors, thereby potentially encouraging synergistic effects between the stem cell properties and those of the trophic factors. The trophic factors, brain-derived neurotropic factor (BDNF), glial cell-derived neurotropic factor (GDNF), fibroblast growth factor (FGF) 2, and insulin-like growth factor (IGF) 1, in particular, have demonstrated neuroprotective actions in a number of animal models. Importantly, we use a nonviral approach, thereby minimizing the potential risk for DNA integration and tumor formation. The present study involved the development of a nonviral reprogramming system to transform adult mature mouse fibroblasts into progressive stages of cell development. We also tailored these stem cells to individually express each of the trophic factors, including BDNF, GDNF, FGF2, and IGF1. Significantly, central infusion of BDNF-expressing stem cells prevented the in vivo loss of neurons associated with infusion of the endotoxin, lipopolysaccharide (LPS). This is particularly important in light of the role of inflammatory processes that are posited to play in virtually all neurodegenerative states. Hence, the present results support the utility of using combined gene and cell-targeting approaches for neuronal pathology.
    Molecular Neurobiology 03/2014; 50(2). DOI:10.1007/s12035-014-8680-2 · 5.14 Impact Factor
Show more